Aurobindo Pharma Q1 FY27 Revenue Up 16.3% YoY to ₹9,150 Cr

Aurobindo Pharma announced its consolidated financial results for the first quarter ended June 30, 2026, reporting a 16.3% year-on-year increase in Revenue from Operations to INR 9,150 Cr. The company saw significant growth across its businesses, with US revenue up 8.1% to INR 3,770 Cr and Europe revenue up 25.6% to INR 2,937 Cr. Growth Markets also performed strongly, with a 37.7% YoY increase to INR 1,063 Cr. Net Profit for the quarter stood at INR 1,032 Cr, a 25.2% increase YoY. The company highlighted a strong net cash position and generated free cash flow of USD 98 million during the quarter. Aurobindo Pharma also received final approval for 10 products from the USFDA.